跳至主要内容
临床试验/NCT00498303
NCT00498303已完成3 期

A Phase III, Multicenter, Uncontrolled, Open-Label Study to Evaluate Safety and Immunogenicity of Preservative Free, Inactivated Split Influenza Vaccine, Using the Strain Composition 2007/2008 When Administered to Adult and Elderly Subjects

Novartis2 个研究点 分布在 1 个国家目标入组 120 人开始时间: 2007年6月1日最近更新:
适应症

试验速览

阶段
3 期
状态
已完成
发起方
Novartis
入组人数
120
试验地点
2
主要终点
evaluate the antibody response to each influenza vaccine antigen, as measured by haemagglutination inhibition (HI) test on Day 0 and on Day 21

研究概览

简要总结

Annual trial for registration of trivalent split influenza vaccine with the strain composition of the season 2007/2008 in healthy adult and elderly subjects

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Single Group
主要目的
Prevention
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • ≥ 18 years of age, mentally competent, willing and able to give informed consent prior to study entry
  • available for all the visits scheduled in the study and able to comply with all study requirements
  • in good health as determined by: medical history, physical examination, clinical judgment of the investigator

排除标准

  • 未提供

结局指标

主要结局

evaluate the antibody response to each influenza vaccine antigen, as measured by haemagglutination inhibition (HI) test on Day 0 and on Day 21

evaluate safety of trivalent split influenza vaccine

次要结局

未报告次要终点

研究者

发起方
Novartis
申办方类型
Industry

研究点 (2)

Loading locations...

相似试验